In Brief: Novoste Beta-Cath
This article was originally published in The Gray Sheet
Novoste Beta-Cath: Feasibility study of the intracoronary radiation therapy device for reduction of restenosis "suggests 70% reduction in the rate of restenosis" with use of the system compared to historical controls, according to data presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. the week of Sept. 22 by researcher Spencer King, MD. The Beta Energy Restenosis Trial (BERT) included follow-up data from 35 patients and demonstrated an overall restenosis rate of 11%. The firm's Phase II trial commenced in July ("The Gray Sheet" Aug. 18, In Brief)...
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.